The 180 °N project is funded by Tromsø Research Foundation and Trond Mohn Foundation, both based on donations from Trond Mohn.
The 180 °N project is a new national research collaboration led by Universities and University Hospitals in Tromsø, Trondheim and Bergen. Stavanger University Hospital also participates as a partner in one of the projects. The 180 °N project aims to develop methods for various cancer diseases and neurological disorders, and to improve patient stratification and personalized treatment. The research program starts in 2019 and will last until 2024.
Towards the collaborative goals, the Bergen project focuses on the development of radioactive tracers, Tromsø on preclinical testing, and Trondheim on clinical trials. A close cooperation network in the fields of tracer development, pharmacology, chemistry, (radiation) oncology, (radiation) biology, nuclear medicine, immunology, drug development and machine learning are established. State-of-the-art imaging diagnostic equipment is also funded by private gifts from Trond Mohn to the University Hospitals in the three cities. This allows method and routine transfer between institutions, and that the projects can reinforce each other with knowledge and data from their focus fields.
Tromsø project: Targeting tumor microenvironment Boosting PET-based diagnostics and therapies
The project in Tromsø, led by Assoc. Prof. Rune Sundset, will test the innovative nuclear medicines in vitro and in vivo at the Preclinical Core Facility with the advanced infrastructure in nuclear medicine and radiation biology. Moreover, in order to improve quantification and to monitor therapy-induced changes, novel machine learning methods will be developed and applied to the imaging data. This will be further developed as a clinical tool to facilitate treatment selection and monitoring in routine clinical application. The Coastal Cooperation, with its unique infrastructure and merged experience, will push forward the development of imaging agents, radiotheranostics and patient-specific nuclear therapies.
Work packages (WP) of the Coastal Cooperation Tromsø project
Cancer-Associated Fibroblasts Role in Lung Tumor Responses to Radiotherapy and Immunotherapy
Radiotherapy to Enhance Response Rates to Immunotherapies
Evidences has revealed that local radiotherapy (RT), applied to patients in specific forms, can turn tumors into in situ vaccines. However, systematic studies at the pre-clinical phase on optimal timing and delivery of RT that could synergize with immunotherapies are still inadequate. In this project we propose to study systematically, in pre-clinical mouse models, the local and systemic immuno-responses elicited by RT applied in different schemes, in order to delineate optimal RT regimens for combinatory immunotherapeutic interventions. This project aims to achieve personalized immunization and enhance responses to immunotherapies by means of radiotherapy.